NRG1 Fusion

LEXINGTON, Massachusetts, United States – May 6, 2026 Partner Therapeutics has announced that the U.S. Food and Drug Administration...

LEXINGTON, MASSACHUSETTS, USA, April 14, 2026 Partner Therapeutics, Inc. has announced the submission of a supplemental Biologics License Application...

LEXINGTON, Mass., February 20, 2026 — New findings from a post hoc analysis of the ongoing eNRGy trial reveal...

WALTHAM, Mass., Feb. 2026 — Partner Therapeutics announced that zenocutuzumab-zbco, an investigational bispecific antibody therapy, has received U.S. FDA...

LEXINGTON, Mass., October 23, 2025– Partner Therapeutics, Inc. (PTx), a fully integrated biotechnology company, announced that the U.S. Food...